By recreating a fetal liver niche, FLOs show how liver and immune cells co-develop. Learn more about new groundbreaking ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...

Sidra Medicine completes Qatar’s first pediatric allogeneic HSCT, advancing life-saving stem cell care for children with ...

The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

Infusions of platelet factor 4 (PF4) have reversed aging in human hematopoietic stem cells (HSCs), the precursors of a range of blood and immune cells. A team from the University of Illinois Chicago ...

Doha: Sidra Medicine has announced the successful completion of its first pediatric allogeneic hematopoietic stem cell transplantation (HSCT), ...

Motixafortide alone and in combination with natalizumab can support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a single apheresis cycle ...

The U.S. FDA’s green lighting of Omeros Corp.’s Yartemlea (narsoplimab) makes it the first approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a ...

Credit: Getty Images. The goal of HCT is to cure an underlying malignancy or hematologic disorder. The procedure can be performed in an inpatient or outpatient setting. Each setting is associated with ...